The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until, and including, 2038.

CEO Mikael Lindstam comments:

"The fact that we have now received notification that China intends to grant a patent for our patent family 2 is of great importance to Aptahem. China is one of the world's largest and fastest growing markets for pharmaceutical development and biotechnology, and patent protection here strengthens both our global position and our attractiveness to potential partners. This means a clear increase in value for our development portfolio and is an important step in creating long-term business value."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.